FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077772880> ?p ?o ?g. }

• W2077772880 endingPage "27" @default.
• W2077772880 startingPage "27" @default.
• W2077772880 abstract "Back to table of contents Previous article Next article Clinical & Research NewsFull AccessOnce Down for the Count, Lithium Lives to Fight AgainJim RosackJim RosackSearch for more papers by this authorPublished Online:5 Jul 2002https://doi.org/10.1176/pn.37.13.0027The importance of the topic was underscored by the overflow crowd attending a workshop on the last day of APA’s 2002 annual meeting in May. The psychiatrists simply wanted to know about the latest information on a very old “friend”—lithium.Frederick Goodwin, M.D. (right), discusses combining lithium with another mood stabilizer, while Eric Smith, M.D., looks on.Eric Smith, M.D., a PGY-2 psychiatry resident at Boston University Medical Center chaired the workshop, titled “Lithium Revisited.” He was joined by bipolar experts Frederick Goodwin, M.D., research professor of psychiatry and behavioral sciences at the George Washington University School of Medicine, and James W. Jefferson, M.D., distinguished senior scientist at the Madison Institute of Medicine and director of the Lithium Information Center, who served as discussants.Both Goodwin and Jefferson praised Smith for an excellent overview of a drug that Goodwin characterized as “born well before the chair of this workshop!”Indeed, Smith reviewed 50 years of experience in using lithium in bipolar states, noting that by far, it is the one drug in all of psychopharmacology with a “fully documented history of efficacy.” There are, Smith noted, over a dozen placebo-controlled clinical trials documenting the drug’s effects in reducing the frequency of manic episodes as well as stabilizing cycling between mania and depression, on average producing a fourfold reduction of episodes of mania or depression.Not only is the drug a well-established mood stabilizer, Smith said, but “recent research has documented that lithium has some neuroprotective effects, and it is by far the most effective treatment for reducing—by as much as 50 percent—the overwhelming mortality associated with bipolar disorder.” Lithium is the only drug that has been documented to decrease significantly both suicidal gestures and decrease the number of completed suicides among patients with bipolar disorder.“But,” Smith hedged, “it has a huge side-effect profile and correspondingly huge problems with patient compliance. Simply put, patients feel so much better taking it, but they stop taking it to avoid the side effects.”Chronic lithium therapy is commonly associated with nausea, diarrhea, dizziness, and blurry vision. In more severe cases, it is often referred to as “lithium intoxication,” which can be associated with headache, excessive sweating, electrolyte disturbances, ataxia, tremor, seizure, and in severe toxicity, coma leading to death.“Clinicians are always warned to check serum lithium levels,” Smith noted, “but you have to remember that the serum level must be correlated with the clinical response. In some people, toxicity can and does occur at what would on average be considered a therapeutic level.”The accepted therapeutic level, he noted, is being rethought, based on recent research. “A therapeutic level now seems to be in the range of 0.6 to 1.0 milliequivalents per liter rather than what older references said, which was to keep your patients between 0.8 and 1.2.” Keeping the serum levels lower achieves equal efficacy, Smith said, but can drastically reduce side effects. In addition, using long-acting lithium, given daily at bedtime, also has been shown recently to reduce side effects.Goodwin and Jefferson agreed that lithium is by far the most effective mood stabilizer. They disagreed somewhat on its side-effect profile, especially in the long-term effects of lithium therapy. Goodwin actively champions combination therapy, using lower doses of lithium along with another mood stabilizer—he often adds low doses of divalproex—and has done studies that indicate that patients on combination therapy do just as well symptomatically, while experiencing fewer side effects.Smith noted that a good number of current bipolar experts do believe in lithium and use it frequently, in spite of recent research suggesting that it has fallen out of favor.“As long as you get a good history, talk openly and candidly about the side effects of lithium with your patients, and monitor those side effects over time,” Smith concluded, “lithium is still the drug of choice in bipolar disorder. It is the most effective medication we have and, when appropriately managed, is quite safe.”The Web site for the Lithium Information Center is www.miminc.org/aboutlithinfoctr.html. ▪ ISSUES NewArchived" @default.
• W2077772880 created "2016-06-24" @default.
• W2077772880 creator A5008516072 @default.
• W2077772880 date "2002-07-05" @default.
• W2077772880 modified "2023-09-23" @default.
• W2077772880 title "Once Down for the Count, Lithium Lives to Fight Again" @default.
• W2077772880 doi "https://doi.org/10.1176/pn.37.13.0027" @default.
• W2077772880 hasPublicationYear "2002" @default.
• W2077772880 type Work @default.
• W2077772880 sameAs 2077772880 @default.
• W2077772880 citedByCount "0" @default.
• W2077772880 crossrefType "journal-article" @default.
• W2077772880 hasAuthorship W2077772880A5008516072 @default.
• W2077772880 hasConcept C11171543 @default.
• W2077772880 hasConcept C118552586 @default.
• W2077772880 hasConcept C15744967 @default.
• W2077772880 hasConcept C161191863 @default.
• W2077772880 hasConcept C2778541603 @default.
• W2077772880 hasConcept C41008148 @default.
• W2077772880 hasConcept C52119013 @default.
• W2077772880 hasConcept C67101536 @default.
• W2077772880 hasConcept C71924100 @default.
• W2077772880 hasConcept C95457728 @default.
• W2077772880 hasConceptScore W2077772880C11171543 @default.
• W2077772880 hasConceptScore W2077772880C118552586 @default.
• W2077772880 hasConceptScore W2077772880C15744967 @default.
• W2077772880 hasConceptScore W2077772880C161191863 @default.
• W2077772880 hasConceptScore W2077772880C2778541603 @default.
• W2077772880 hasConceptScore W2077772880C41008148 @default.
• W2077772880 hasConceptScore W2077772880C52119013 @default.
• W2077772880 hasConceptScore W2077772880C67101536 @default.
• W2077772880 hasConceptScore W2077772880C71924100 @default.
• W2077772880 hasConceptScore W2077772880C95457728 @default.
• W2077772880 hasIssue "13" @default.
• W2077772880 hasLocation W20777728801 @default.
• W2077772880 hasOpenAccess W2077772880 @default.
• W2077772880 hasPrimaryLocation W20777728801 @default.
• W2077772880 hasRelatedWork W116012685 @default.
• W2077772880 hasRelatedWork W1884192967 @default.
• W2077772880 hasRelatedWork W2036405309 @default.
• W2077772880 hasRelatedWork W2040661167 @default.
• W2077772880 hasRelatedWork W2043009872 @default.
• W2077772880 hasRelatedWork W2100418725 @default.
• W2077772880 hasRelatedWork W2513010588 @default.
• W2077772880 hasRelatedWork W2748952813 @default.
• W2077772880 hasRelatedWork W2899084033 @default.
• W2077772880 hasRelatedWork W39809481 @default.
• W2077772880 hasVolume "37" @default.
• W2077772880 isParatext "false" @default.
• W2077772880 isRetracted "false" @default.
• W2077772880 magId "2077772880" @default.
• W2077772880 workType "article" @default.